• Je něco špatně v tomto záznamu ?

Stereotactic Radiosurgery for World Health Organization Grade 2 and 3 Oligodendroglioma: An International Multicenter Study

AM. Langlois, C. Iorio-Morin, J. Kallos, A. Niranjan, LD. Lunsford, S. Peker, Y. Samanci, DJ. Park, GH. Barnett, R. Liscak, G. Simonova, S. Pikis, G. Mantziaris, J. Sheehan, CC. Lee, HC. Yang, GN. Bowden, D. Mathieu

. 2025 ; 96 (4) : 870-880. [pub] 20240920

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009373

BACKGROUND AND OBJECTIVES: Oligodendrogliomas are primary brain tumors classified as isocitrate deshydrogenase-mutant and 1p19q codeleted in the 2021 World Health Organization Classification of central nervous system tumors. Surgical resection, radiotherapy, and chemotherapy are well-established management options for these tumors. Few studies have evaluated the efficacy of stereotactic radiosurgery (SRS) for oligodendroglioma. As these tumors are less infiltrative than astrocytomas and typically recur locally, focal therapy such as SRS is an appealing option. METHODS: This study was performed through the International Radiosurgery Research Foundation. The objective was to collect retrospective multicenter data on tumor control, clinical response, and morbidity after SRS for oligodendroglioma. Inclusion criteria were age of 18 years or more, single-fraction SRS, and histological confirmation of grade 2 or 3 oligodendroglioma. The primary end points were progression-free survival (PFS) and overall survival from SRS. Secondary end points included clinical evolution and occurrence of adverse radiation events or other complications. Descriptive statistics, Kaplan-Meier analyses, and univariate and multivariate analyses were performed. RESULTS: Eight institutions submitted data for a total of 55 patients. The median follow-up time was 24 months. The median age at SRS was 46 years, and the median Karnofsky Performance Status was 90%. The median marginal dose used was 15 Gy. The median PFS was 17 months, with actuarial rates of 60% at 1 year, 31% at 2 years, and 24% at 5 years after SRS. Factors significantly associated with worsened PFS were World Health Organization grade 3, previous radiotherapy and chemotherapy, and higher marginal dose. The median overall survival post-SRS was 58 months, with actuarial rates of 92% at 1 year, 83% at 2 years, and 49% at 5 years. Karnofsky Performance Status remained stable post-SRS in 51% and worsened in 47% of patients, most often because of tumor progression (73%). Radiation-induced changes occurred in 30% of patients, of which only 4 were symptomatic. CONCLUSION: SRS is a reasonable management option for patients with oligodendroglioma.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009373
003      
CZ-PrNML
005      
20250429134751.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1227/neu.0000000000003177 $2 doi
035    __
$a (PubMed)39808548
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Langlois, Anne-Marie $u Department of Surgery, Division of Neurosurgery, Centre de recherche du Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke , Québec , Canada
245    10
$a Stereotactic Radiosurgery for World Health Organization Grade 2 and 3 Oligodendroglioma: An International Multicenter Study / $c AM. Langlois, C. Iorio-Morin, J. Kallos, A. Niranjan, LD. Lunsford, S. Peker, Y. Samanci, DJ. Park, GH. Barnett, R. Liscak, G. Simonova, S. Pikis, G. Mantziaris, J. Sheehan, CC. Lee, HC. Yang, GN. Bowden, D. Mathieu
520    9_
$a BACKGROUND AND OBJECTIVES: Oligodendrogliomas are primary brain tumors classified as isocitrate deshydrogenase-mutant and 1p19q codeleted in the 2021 World Health Organization Classification of central nervous system tumors. Surgical resection, radiotherapy, and chemotherapy are well-established management options for these tumors. Few studies have evaluated the efficacy of stereotactic radiosurgery (SRS) for oligodendroglioma. As these tumors are less infiltrative than astrocytomas and typically recur locally, focal therapy such as SRS is an appealing option. METHODS: This study was performed through the International Radiosurgery Research Foundation. The objective was to collect retrospective multicenter data on tumor control, clinical response, and morbidity after SRS for oligodendroglioma. Inclusion criteria were age of 18 years or more, single-fraction SRS, and histological confirmation of grade 2 or 3 oligodendroglioma. The primary end points were progression-free survival (PFS) and overall survival from SRS. Secondary end points included clinical evolution and occurrence of adverse radiation events or other complications. Descriptive statistics, Kaplan-Meier analyses, and univariate and multivariate analyses were performed. RESULTS: Eight institutions submitted data for a total of 55 patients. The median follow-up time was 24 months. The median age at SRS was 46 years, and the median Karnofsky Performance Status was 90%. The median marginal dose used was 15 Gy. The median PFS was 17 months, with actuarial rates of 60% at 1 year, 31% at 2 years, and 24% at 5 years after SRS. Factors significantly associated with worsened PFS were World Health Organization grade 3, previous radiotherapy and chemotherapy, and higher marginal dose. The median overall survival post-SRS was 58 months, with actuarial rates of 92% at 1 year, 83% at 2 years, and 49% at 5 years. Karnofsky Performance Status remained stable post-SRS in 51% and worsened in 47% of patients, most often because of tumor progression (73%). Radiation-induced changes occurred in 30% of patients, of which only 4 were symptomatic. CONCLUSION: SRS is a reasonable management option for patients with oligodendroglioma.
650    12
$a oligodendrogliom $x chirurgie $x patologie $7 D009837
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a nádory mozku $x chirurgie $7 D001932
650    _2
$a dospělí $7 D000328
650    12
$a radiochirurgie $x metody $7 D016634
650    _2
$a retrospektivní studie $7 D012189
650    12
$a Světová zdravotnická organizace $7 D014944
650    _2
$a senioři $7 D000368
650    _2
$a mladý dospělý $7 D055815
650    _2
$a výsledek terapie $7 D016896
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a doba přežití bez progrese choroby $7 D000077982
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Iorio-Morin, Christian $u Department of Surgery, Division of Neurosurgery, Centre de recherche du Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke , Québec , Canada
700    1_
$a Kallos, Justiss $u Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh , Pennsylvania , USA
700    1_
$a Niranjan, Ajay $u Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh , Pennsylvania , USA
700    1_
$a Lunsford, L Dade $u Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh , Pennsylvania , USA
700    1_
$a Peker, Selcuk $u Department of Neurosurgery, Koc University School of Medicine, Istanbul , Turkey
700    1_
$a Samanci, Yavuz $u Department of Neurosurgery, Koc University School of Medicine, Istanbul , Turkey
700    1_
$a Park, David J $u Department of Neurological Surgery, Neurological Institute, Cleveland Clinic, Cleveland , Ohio , USA
700    1_
$a Barnett, Gene H $u Department of Neurological Surgery, Neurological Institute, Cleveland Clinic, Cleveland , Ohio , USA
700    1_
$a Liscak, Roman $u Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague , Czech Republic
700    1_
$a Simonova, Gabriela $u Department of Stereotactic and Radiation Neurosurgery, Na Homolce Hospital, Prague , Czech Republic
700    1_
$a Pikis, Stylianos $u Department of Neurological Surgery, University of Virginia, Charlottesville , Virginia , USA
700    1_
$a Mantziaris, Georgios $u Department of Neurological Surgery, University of Virginia, Charlottesville , Virginia , USA
700    1_
$a Sheehan, Jason $u Department of Neurological Surgery, University of Virginia, Charlottesville , Virginia , USA
700    1_
$a Lee, Cheng-Chia $u Department of Radiation Oncology and Neurological Surgery, Neurological Institute, Taipei Veteran General Hospital, Taipei , Taiwan
700    1_
$a Yang, Huai-Che $u Department of Radiation Oncology and Neurological Surgery, Neurological Institute, Taipei Veteran General Hospital, Taipei , Taiwan
700    1_
$a Bowden, Greg N $u Department of Neurosurgery, University of Alberta, Edmonton , Alberta , Canada
700    1_
$a Mathieu, David $u Department of Surgery, Division of Neurosurgery, Centre de recherche du Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke , Québec , Canada $1 https://orcid.org/0000000320296315
773    0_
$w MED00003511 $t Neurosurgery $x 1524-4040 $g Roč. 96, č. 4 (2025), s. 870-880
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39808548 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134747 $b ABA008
999    __
$a ok $b bmc $g 2311008 $s 1246454
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 96 $c 4 $d 870-880 $e 20240920 $i 1524-4040 $m Neurosurgery $n Neurosurgery $x MED00003511
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace